{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:46:57Z","timestamp":1769780817175,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"DOI":"10.7759\/cureus.102589","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:49:16Z","timestamp":1769726956000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report"],"prefix":"10.7759","author":[{"given":"Ryota","family":"Amano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril V","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al.. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023, 22:383-94. 10.1016\/s1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF Jr.","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, et al.. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021, 20:526-36. 10.1016\/s1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi C","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, et al.. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025, 24:105-16. 10.1016\/S1474-4422(24)00498-8","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard JF Jr.","year":"2023","unstructured":"Howard JF Jr., Bresch S, Genge A, et al.. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023, 22:395-406. 10.1016\/s1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe GI","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999, 52:1487-9. 10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"1","author":"Jaretzki A 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al.. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000, 1:327-34. 10.1016\/s0003-4975(00)01595-2","journal-title":"Ann Thorac Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard JF Jr.","year":"2024","unstructured":"Howard JF Jr., Bresch S, Farmakidis C, et al.. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord. 2024, 17:3186. 10.1177\/17562864241243186","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns TM","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K, et al.. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016, 54:1015-22. 10.1002\/mus.25198","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200436","article-title":"AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis","volume":"12","author":"Khani-Habibabadi F","year":"2025","unstructured":"Khani-Habibabadi F, Roy B, Pham MC, Obaid AH, Filipek B, Nowak RJ, O'Connor KC. AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2025, 12:e200436. 10.1212\/NXI.0000000000200436","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80203","article-title":"Zilucoplan for successful early weaning from mechanical ventilation and avoiding tracheostomy in an 85-year-old woman experiencing myasthenic crisis: a case report","volume":"17","author":"Ito S","year":"2025","unstructured":"Ito S, Sugimoto T, Naito H, et al.. Zilucoplan for successful early weaning from mechanical ventilation and avoiding tracheostomy in an 85-year-old woman experiencing myasthenic crisis: a case report. Cureus. 2025, 17:e80203. 10.7759\/cureus.80203","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.11477\/mf.188160960770080921","article-title":"Myasthenia gravis treated with zilucoplan prior to extended transsternal thymectomy for the prevention of myasthenic crisis: a case report (Article in Japanese)","volume":"77","author":"Yamanaka N","year":"2025","unstructured":"Yamanaka N, Honda M, Kanda S, Tanaka T, Shimizu F, Koga M, Nakamori M. Myasthenia gravis treated with zilucoplan prior to extended transsternal thymectomy for the prevention of myasthenic crisis: a case report (Article in Japanese). Brain Nerve. 2025, 77:921-5. 10.11477\/mf.188160960770080921","journal-title":"Brain Nerve"},{"key":"ref13","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). (2025). Accessed. January 8, 2026: https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/3999471G1020_1?user=1."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman U","year":"2021","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S. The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve. 2021, 64:212-5. 10.1002\/mus.27326","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13113-0","article-title":"Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis","volume":"272","author":"Hewamadduma C","year":"2025","unstructured":"Hewamadduma C, Freimer M, Genge A, et al.. Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. J Neurol. 2025, 272:457. 10.1007\/s00415-025-13113-0","journal-title":"J Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441711-rapid-symptomatic-improvement-and-long-term-minimal-symptom-expression-in-a-myasthenia-gravis-patient-treated-with-zilucoplan-without-maintenance-cholinesterase-inhibitors-corticosteroids-or-immunosuppressants-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:49:17Z","timestamp":1769726957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441711-rapid-symptomatic-improvement-and-long-term-minimal-symptom-expression-in-a-myasthenia-gravis-patient-treated-with-zilucoplan-without-maintenance-cholinesterase-inhibitors-corticosteroids-or-immunosuppressants-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.102589","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}